DE60239741D1 - Antigenpräsentierende zellen, verfahren zu ihrer herstellung sowie ihre verwendung für krebsimpfstoffe - Google Patents

Antigenpräsentierende zellen, verfahren zu ihrer herstellung sowie ihre verwendung für krebsimpfstoffe

Info

Publication number
DE60239741D1
DE60239741D1 DE60239741T DE60239741T DE60239741D1 DE 60239741 D1 DE60239741 D1 DE 60239741D1 DE 60239741 T DE60239741 T DE 60239741T DE 60239741 T DE60239741 T DE 60239741T DE 60239741 D1 DE60239741 D1 DE 60239741D1
Authority
DE
Germany
Prior art keywords
cells
associated antigens
tumor associated
antigen presenting
presenting cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60239741T
Other languages
German (de)
English (en)
Inventor
Santis Rita De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of DE60239741D1 publication Critical patent/DE60239741D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE60239741T 2001-07-30 2002-07-25 Antigenpräsentierende zellen, verfahren zu ihrer herstellung sowie ihre verwendung für krebsimpfstoffe Expired - Lifetime DE60239741D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IT2001/000419 WO2003012085A1 (en) 2001-07-30 2001-07-30 Antigen presenting cells, method for their preparation and their use for cancer vaccines
PCT/IT2002/000488 WO2003012086A1 (en) 2001-07-30 2002-07-25 Antigen presenting cells, method for their preparation and their use for cancer vaccines

Publications (1)

Publication Number Publication Date
DE60239741D1 true DE60239741D1 (de) 2011-05-26

Family

ID=11133712

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60239741T Expired - Lifetime DE60239741D1 (de) 2001-07-30 2002-07-25 Antigenpräsentierende zellen, verfahren zu ihrer herstellung sowie ihre verwendung für krebsimpfstoffe

Country Status (16)

Country Link
US (3) US20030119187A1 (https=)
EP (1) EP1412485B1 (https=)
JP (1) JP2004536615A (https=)
KR (1) KR100916670B1 (https=)
CN (1) CN100591762C (https=)
AT (1) ATE505533T1 (https=)
AU (1) AU2002334387B2 (https=)
BR (1) BR0211520A (https=)
CA (1) CA2453522C (https=)
DE (1) DE60239741D1 (https=)
DK (1) DK1412485T3 (https=)
ES (1) ES2367256T3 (https=)
HU (1) HUP0401753A3 (https=)
MX (1) MXPA04000885A (https=)
PL (1) PL211907B1 (https=)
WO (2) WO2003012085A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012085A1 (en) 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
KR101192652B1 (ko) * 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
US7695725B2 (en) * 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
KR101173871B1 (ko) * 2003-02-06 2012-08-16 앤저 테라퓨틱스 인코퍼레이티드 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법
DE10329240A1 (de) * 2003-06-24 2005-01-20 Epigenomics Ag Verfahren zur Analyse des Cytosin-Methylierungsstatus von Cancer-Testis-Antigenen für eine individualisierte Immuntherapie
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
CN1910284B (zh) * 2004-01-20 2011-04-06 爱知县 由HLA-A2402-限制的Ep-CAM-特异的CTL识别的表位/肽及其应用
JP4925033B2 (ja) * 2004-02-03 2012-04-25 学校法人 久留米大学 ストレス誘導抗アポトーシス分子（ｉｅｘ−１）由来ペプチド
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
WO2007011693A2 (en) 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
GB0700058D0 (en) * 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
EP2510086A4 (en) * 2009-12-08 2013-05-22 Wolf Wilson Mfg Corp IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES
PL2729008T3 (pl) * 2011-07-07 2017-10-31 Res Cancer Institute Of America Systemy, sposoby i formulacje do leczenia raka
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
EP3431142B1 (en) 2011-08-30 2020-06-17 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
HRP20200521T1 (hr) * 2012-10-30 2020-08-07 Mei Pharma, Inc. Kombinacijske terapije za liječenje kemorezistentnih rakova
US9562219B2 (en) * 2013-12-27 2017-02-07 SOTIO a.s. Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer
JP2018515421A (ja) * 2015-05-22 2018-06-14 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 複数用量注射準備済樹状細胞ワクチンの製造
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
CN105132371B (zh) * 2015-07-24 2016-05-25 北京鼎成肽源生物技术有限公司 体外提呈、激活dc细胞的方法及其应用
US10052372B2 (en) * 2016-05-24 2018-08-21 Tessa Therapeutics Pte Ltd T cell expansion
US11890292B2 (en) 2017-02-27 2024-02-06 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2018170457A1 (en) 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
RU2020108580A (ru) 2017-08-03 2021-09-03 Оцука Фармасьютикал Ко., Лтд. Лекарственное соединение и способы его очистки
CN107557333B (zh) * 2017-10-16 2018-07-31 北京鼎成肽源生物技术有限公司 一种用于细胞治疗的新抗原呈递细胞的制备方法
US12213958B2 (en) 2017-11-17 2025-02-04 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
KR102319259B1 (ko) 2019-07-26 2021-10-28 정재웅 지반천공기용 확장리더 안전제어장치
WO2021027057A1 (zh) * 2019-08-15 2021-02-18 成都冕康生物科技有限公司 一种针对ebv病毒抗原的b细胞疫苗及其制备方法
CN114099655A (zh) * 2021-11-16 2022-03-01 苏州大学 一种预防或治疗癌症的疫苗系统及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1185811A (zh) * 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
CA2302316A1 (en) * 1997-09-15 1999-03-25 Genetic Immunity, Llc. Method of delivering genes to antigen presenting cells of the skin
US6613753B2 (en) 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
WO2003012085A1 (en) 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines

Also Published As

Publication number Publication date
CA2453522A1 (en) 2003-02-13
US20040185563A1 (en) 2004-09-23
JP2004536615A (ja) 2004-12-09
EP1412485B1 (en) 2011-04-13
CN100591762C (zh) 2010-02-24
US7883889B2 (en) 2011-02-08
BR0211520A (pt) 2004-09-14
CA2453522C (en) 2013-04-30
HUP0401753A3 (en) 2011-04-28
DK1412485T3 (da) 2011-08-01
PL211907B1 (pl) 2012-07-31
ATE505533T1 (de) 2011-04-15
MXPA04000885A (es) 2004-06-03
PL367617A1 (en) 2005-03-07
WO2003012085A1 (en) 2003-02-13
KR20040021662A (ko) 2004-03-10
CN1537161A (zh) 2004-10-13
HUP0401753A2 (hu) 2004-11-29
EP1412485A1 (en) 2004-04-28
WO2003012086A1 (en) 2003-02-13
AU2002334387B2 (en) 2007-10-04
HK1068913A1 (zh) 2005-05-06
KR100916670B1 (ko) 2009-09-08
US20030119187A1 (en) 2003-06-26
ES2367256T3 (es) 2011-10-31
US20050002920A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
DE60239741D1 (de) Antigenpräsentierende zellen, verfahren zu ihrer herstellung sowie ihre verwendung für krebsimpfstoffe
DE602006011310D1 (de) KRISTALLINE FORM VON 1-CHLOR-4-(ß-D-GLUCOPYRANOS-1-YL)-2-Ä4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYLÜBENZOL, VERFAHREN ZU DESSEN HERSTELLUNG UND DESSEN VERWENDUNG ZUR HERSTELLUNG VON MEDIKAMENTEN
TW200617172A (en) Enzymatic preparation of (meth)acrylic esters
ATE468111T1 (de) Zusammensetzung in mikropellets mit kontrollierter freisetzung von physiologischen wirksubstanzen, verfahren zu ihrer herstellung und ihre verwendung im zootechnischen sektor
WO2005113747A3 (de) Multizelluläre gewebe- und organkultursysteme
IL178516A0 (en) Methods and products for producing lattices of emr-treated islets in tissues, and uses therefor
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
PE20120015A1 (es) Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico
DE602005019064D1 (de) Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
WO2005013901A3 (en) Oligomeric compounds and compositions for use in modulation of small non-coding rnas
ES2534303T3 (es) Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
EP1747183A4 (en) METHOD FOR THE PRODUCTION OF ALKOXYLATING CATALYSTS AND THEIR USE IN ALKOXYLATION PROCESSES
WO2005123736A8 (de) Neue 2-benzylaminodihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
WO2010000127A9 (en) Method to induce and expand therapeutic alloantigen- specific human regulatory t cells in large-scale
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
TW200510011A (en) A method for regeneration of bone
SE0000597D0 (sv) Novel antibody
WO2006105255A3 (en) Cancer vaccines and therapeutic methods
ATE487730T1 (de) Verfahren zur herstellung eines oxaliplatins
DE112006001500A5 (de) Verfahren zum Erhalt von Primärkulturtumorzellen aus Tumorgewebe, insbesondere Mammakarzinom, Primärkulturtumorzellen und deren Verwendung
CN111868265A (zh) Dna重组修复功能评分rds在癌症治疗中的用途
ATE315406T1 (de) Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen
DE602006009117D1 (de) Verfahren zur identifizierung von die stresstoleranz in hefe erhöhenden genen sowie verwendung dieser gene zur verbesserung von hefestämmen
PT1848447E (pt) Agente de regeneração de tecido biológico e método para a preparação e utilização do mesmo

Legal Events

Date Code Title Description
R082 Change of representative

Ref document number: 1412485

Country of ref document: EP

Representative=s name: MUELLER & SCHUBERT, 10178 BERLIN, DE

R082 Change of representative

Ref document number: 1412485

Country of ref document: EP

Representative=s name: MUELLER & SCHUBERT, 10178 BERLIN, DE